Eversept Partners LP Has $156.71 Million Holdings in United Therapeutics Corporation $UTHR

Eversept Partners LP grew its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 4.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 264,271 shares of the biotechnology company’s stock after purchasing an additional 11,679 shares during the quarter. United Therapeutics comprises about 8.3% of Eversept Partners LP’s investment portfolio, making the stock its largest position. Eversept Partners LP’s holdings in United Therapeutics were worth $156,707,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the business. Torren Management LLC acquired a new stake in shares of United Therapeutics in the fourth quarter valued at $26,000. Activest Wealth Management raised its holdings in shares of United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 56 shares during the last quarter. WealthCollab LLC lifted its position in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares in the last quarter. Rakuten Securities Inc. grew its holdings in United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares during the last quarter. Finally, Entrust Financial LLC bought a new stake in United Therapeutics during the 4th quarter worth about $31,000. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Down 0.1%

Shares of UTHR stock opened at $527.94 on Tuesday. The stock has a 50-day moving average price of $547.10 and a 200 day moving average price of $531.86. The firm has a market cap of $22.41 billion, a price-to-earnings ratio of 19.49, a PEG ratio of 1.77 and a beta of 0.58. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. During the same period in the prior year, the firm posted $6.63 earnings per share. The business’s revenue for the quarter was down 1.6% compared to the same quarter last year. Sell-side analysts predict that United Therapeutics Corporation will post 26.65 earnings per share for the current fiscal year.

Analysts Set New Price Targets

UTHR has been the subject of a number of research analyst reports. HC Wainwright boosted their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. Raymond James Financial assumed coverage on shares of United Therapeutics in a research note on Friday, April 10th. They set an “outperform” rating and a $700.00 price target on the stock. Royal Bank Of Canada raised their price target on shares of United Therapeutics from $701.00 to $704.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. Finally, Bank of America dropped their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $648.33.

Insider Transactions at United Therapeutics

In related news, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Monday, July 13th. The shares were sold at an average price of $535.99, for a total transaction of $5,091,905.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $21,714,562.87. The trade was a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $552.56, for a total transaction of $4,586,248.00. Following the completion of the transaction, the executive vice president owned 45,172 shares in the company, valued at $24,960,240.32. This represents a 15.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 493,833 shares of company stock worth $275,841,047 in the last quarter. 8.60% of the stock is owned by company insiders.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.